Colorectal carcinoma (CRC) · FOLFOX + Cetuximab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-FOLFOX-CETUX |
| ID | IND-CRC-METASTATIC-2L-EGFRI-RECHALLENGE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ rechallenge for biomarker-selected RAS-WT mCRC. ESCAT IIA. Trial- specific sources (CHRONOS, CITRIC) not in KB yet — flagged for CSD-4.5. Re-uses existing REG-FOLFOX-CETUX (FOLFIRI+cetux equally acceptable rechallenge backbone — future regimen authoring). Routed to line_of_therapy=3 because rechallenge requires intervening EGFR-free 2L line; algorithm step ras_egfri_check fires the routing.
Used By
Algorithms
ALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2L